Equillium Gets Australian Clearance for Phase 1 Trial of Ulcerative Colitis Drug Candidate EQ504

MT newswire2026/10/05 21:06

05:06 PM EDT, 10/05/2026 (MT Newswires) -- Equillium (EQ) said Monday it received ethics committee approval and regulatory clearance in Australia for a Phase 1 trial of EQ504, an oral drug it is developing for ulcerative colitis, and expects to begin dosing healthy participants by early November. The company received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration under the Clinical Trial Notification scheme. The randomized, double-blinded, placebo-controlled, single-center trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral EQ504 doses ranging from 0.1 mg to 3.0 mg. Equillium said that, subject to supportive Phase 1 data, it expects to start a placebo-controlled proof-of-concept study in patients with moderately to severely active ulcerative colitis in the second half of 2027.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

The value of cryptocurrency assets held by the U.S. government has shrunk by $16 billion from last year’s peak.

AiCoin•2026/10/11 03:23

Copper prices approach historic highs! UBS remains bullish: "Still most optimistic"

华尔街见闻•2026/10/11 01:57

A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year

BeInCrypto•2026/10/10 22:48

The number of stablecoin holders on the Solana chain has surpassed 14 million.

AiCoin•2026/10/10 21:35